Assessment of Clinical Effects of Coenzyme Q10 Levels in COVID-19 Patients in Intensive Care Unit
Our Study Will be Carried Out in Hacettepe University Anesthesiology and Reanimation Intensive Care Unit. COVID-19 Positive or Suspected Patients Will be Admitted to the Unit. Coenzyme Q10 Levels Will be Checked in the First Day of Hospitalization and Once a Week. The Relationship Between Results and Clinical Course Will be Evaluated.
1 other identifier
observational
150
1 country
1
Brief Summary
The study will be done in Hacettepe University Anesthesiology and Reanimation Intensive Care Unit. The investigators will accept COVID-19 diagnosed or suspected patients to the ICU. In the first day of hospitalization and after that once a week, the investigators will take blood samples from the patients to evaluate Coenzyme q10 levels. Our hypothesis is that there is a relationship between low coenzyme q10 levels and poor clinical outcome.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2021
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2021
CompletedFirst Submitted
Initial submission to the registry
September 22, 2021
CompletedFirst Posted
Study publicly available on registry
September 28, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2022
CompletedMarch 17, 2022
March 1, 2022
1.7 years
September 22, 2021
March 15, 2022
Conditions
Outcome Measures
Primary Outcomes (3)
mortality
yes or no
from the first day of hospitalization until the date of death from any cause
duration of mechanical ventilation
days
from the first day of hospitalization and during ICU stay period
duration of vasopressor agent requirement
days
from the first day of hospitalization and during ICU stay period
Secondary Outcomes (4)
any organ failure
from the first day of hospitalization until the date of death from any cause or discharge from ICU
new thromboembolic event
from the first day of hospitalization until the date of death from any cause or discharge from ICU
ICU stay period
from the first day of hospitalization until the date of death from any cause or discharge from ICU
hospital stay period
from the first day of discharge from ICU to ward until the date of death or discharge from the hospital
Study Arms (2)
COVID-19 positive patients
COVID-19 negative patients
Interventions
weekly blood sample - coenzym q10 levels
Eligibility Criteria
Hacettepe University Anesthesiology and Reanimation Intensive Care Unit
You may not qualify if:
- being under the age of 18
- being pregnant
- patient refusal
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hacettepe University Hospital
Ankara, Altındağ, 06230, Turkey (Türkiye)
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Research assistant
Study Record Dates
First Submitted
September 22, 2021
First Posted
September 28, 2021
Study Start
January 1, 2021
Primary Completion
October 1, 2022
Study Completion
December 1, 2022
Last Updated
March 17, 2022
Record last verified: 2022-03